[ad_1]
The health
AFP
Image of expression
A subcutaneous device has proven its ability to protect people from HIV infection for one year.
The implantable device, a new Merck project, has been successful in rodents and monkeys and has been secured for 3 months with 12 human volunteers.
The implanted device slowly releases a new type of antiretroviral drug (ARV), called islatravir or MK-8591, to prevent HIV infection.
Scientists from pharmaceutical company Merck presented the results of the first clinical trial at the International Society AIDS Conference in Mexico City, which demonstrated the safe use of the device in humans.
The most recently implemented device in the new wave of HIV prevention devices that use antiretrovirals to prevent infections, or PREP (Prevention Before Exposure)
Scientists conducted clinical trials of the device on 12 human volunteers for three months and found that not only was it safe, but that participants were able to contain larger amounts of drug in their system than was thought by patients. scientists.
"If broader studies show that the system is effectively blocking HIV, it can be adopted internationally by the public over the next five years," said Anton Pozniak, president of the International AIDS Society.
Human experiments, which have not yet been publicly discussed, will need to confirm whether the implantable device, which can operate for one year with drugs, will be effective for 12 months.
Source: Daily Mail
[ad_2]
Source link
